- Cash and cash equivalents of €3.2
million at December 31, 2018
- Ramping up of the industrial
partnership strategy on the in vitro diagnostics and research
markets
- €5 million equity refinancing project
with Winance to extend the financial visibility to mid-2020
- Restructuring project aiming to cut
operating costs by 20% and refocus the strategy on industrial
partnerships
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a company
specialized in the development of in-vitro diagnostic (IVD) tests
for the early detection of cancers and genetic diseases and
applications for life sciences research (LSR), informs its
shareholders that an Extraordinary Shareholders’ Meeting will be
held on February 15, 2019 at 9.30 am CET at Simon & Associés,
47 rue de Monceau – 75008 Paris, and provides an update on its
financial situation.
Genomic Vision had cash and cash equivalents of €3.2 million at
December 31, 2018 versus €1.7 million at September 30, 2018. This
figure includes €2.5 million from the drawdown of the final 3
tranches of the current OCABSA financing program during the fourth
quarter of 2018 and €0.3 million via an interest-free loan from
Quest Diagnostics maturing on March 31, 2019, secured by certain
patents. This cash position shows a net cash burn of €1.3 million
over the period.
Over the 2nd half of 2018, the Company intensified its prominent
industrial partnership strategy:
- signing, on August 6, 2018, of a
partnership with the National Centre for Plant Genomic Resources
(CNRGV), which belongs to the French National Institute for
Agricultural Research (INRA), to develop a new technique for plant
genome analysis;
- finalization, on August 9, 2018, of a
licensing agreement on molecular combing technology with European
Equity Partners (EEP), with the aim of creating a state-of-the-art
bioanalytical services company offering specific analytical
services in bioprocessing;
- setting up, on the basis of the
positive results of the clinical study in cervical cancer detection
(HPV test) published at the end of October 2018, of a partnership
with Phyteneo, a specialty pharmaceutical company specializing in
medical devices, for the marketing of the HPV integration test in
the Czech Republic. Phyteneo will be in charge of the CE marking
process and sales of this test in that country. The timetable
foresees the granting of the CE marking in the fourth quarter of
2019, which would enable the pilot marketing to be initiated in the
Czech Republic.
To enable the Company to continue the development of its
activity on the high-potential diagnostics and research markets, an
Extraordinary Shareholders’ Meeting is being convened to notably
discuss a €5 million equity refinancing project put in place with
Winance. Comprising 4 tranches of ABSAs (shares with equity
warrants attached) of between €1 and 1.5 million each (first
tranche of €1.5 million, followed by two tranches of €1 million and
a final tranche of €1.5 million), this additional financing would
allow Genomic Vision to extend its financial visibility through to
mid-2020 and to continue its development efforts through
partnerships and high-value-added projects within the framework of
a refocusing of its strategy combined with a restructuring project
aimed at reducing operating costs by 20%.
This equity financing project foresees the setting up of a €1.5
million bridging loan at the signing of the contract with Winance
that will be repaid with the first tranche of the reserved share
issue. The reserved share issues via the issuance of ABSAs will be
carried out subject to the granting by the AMF (French stock market
authorities) of a visa for the prospectus that will be filed by the
Company and a waiver of Winance’s requirement to table a mandatory
public offering. Indeed, the investor, Winance, will see its
financial holding rise above 30% following the first tranche of
€1.5 million, the second tranche of €1 million or the third tranche
of €1 million, depending on the share price at the time of issuance
of each tranche, which should lead to a mandatory public offering
according to stock market regulations. Winance will therefore ask
the AMF for an exemption from this requirement to table a public
offering pursuant to article 234-9 paragraph 2 of the General
Regulations based on financial situation of Genomic Vision
presenting financial difficulties with uncertainties regarding its
financial visibility beyond the second quarter of 2019 in the
absence of additional financing. Furthermore, Winance will pledge
to contractually limit its voting rights to 20% whatever its
financial stake, in order to confirm its intention of not finding
itself in a situation of control of Genomic Vision.
Moreover, Vesalius Biocapital, longstanding main shareholder of
Genomic Vision, would participate in the refinancing project by
contributing an additional €250 thousand in capital. This
additional contribution is independent of the implementation of the
refinancing project with Winance.
Aaron Bensimon, co-founder and Chairman of Genomic Vision,
comments: “Given our recent achievements, we are confident that
our activity will see an upturn in the upcoming months. In order to
ensure that this positive trend continues, we would like to invite
all of our investors, both institutional and individual, to have
their say on our refinancing project at the Extraordinary
Shareholders’ Meeting that will be held on February 15,
2019. We are counting on their support to contribute to the
ramping up of molecular combing as an indispensable genomic
analysis tool in various high-potential fields, both on the
in-vitro diagnostics market and the life sciences research
applications market.”
The prior notice published today in the BALO (the French
bulletin of mandatory legal notices) will be available on the
Company’s website in the Investors / General Assembly section
(http://www.genomicvision.com/fr/investisseurs/assemblee-generale).
Preparatory documents for this Meeting, including the postal
voting form, will be available on the Company’s website within the
statutory deadline, and no later than January 25, 2019.
Genomic Vision shareholders who wish to vote on the resolutions
can either attend the Extraordinary Shareholders’ Meeting in
person, be represented by another person or send the filled out
voting form to their bank, which must receive it by February 12,
2019.
Should the required quorum not be met, the Extraordinary
Shareholders’ Meeting on the second call would be held on March 4,
2019.
Upcoming financial publication
- FY 2018 revenue: Friday, February 8,
2019 (before market opens)
***
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of
diagnostic solutions for the early detection of cancers and serious
genetic diseases and tools for life sciences research. Through the
DNA Molecular Combing, a strong proprietary technology allowing to
identify genetic abnormalities, GENOMIC VISION stimulates the
R&D productivity of the pharmaceutical companies, the leaders
of the diagnostic industry and the research labs. The Company
develops a robust portfolio of diagnostic tests (breast, ovarian
and colorectal cancers, myopathies) and analysis tools (DNA
replication, biomarkers discovery, gene editing quality control).
Based near Paris, in Bagneux, the Company has approximately 50
employees. GENOMIC VISION is a public listed company listed in
compartment C of Euronext’s regulated market in Paris (Euronext: GV
- ISIN: FR0011799907). For further information, please visit
www.genomicvision.com
Membre des indices CAC® Mid & Small et
CAC® All-Tradable
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the reference
document dated March 28, 2017, available on the web site of Genomic
Vision (www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
Appendix
Features of and arrangements for the ABSA-based financing
plan
Purpose of the financing
This funding provided by Winance (hereinafter the “Investor”)
and supported by Vesalius Biocapital, the Company’s original
shareholder, is intended to provide the Company with additional
financial power in 2019 and beyond so that it can cover its working
capital requirement.
At December 31, 2018, the Company held €3.2 million in cash
and cash equivalents (including €174,000 in a pledged term
account). The Company does not possess sufficient net working
capital to honor its obligations and meet its cash requirements
over the next 12 months.
Given its business plan, which includes a restructuring and a
strategic refocusing drive, the Company believes there are
uncertainties regarding its financial visibility out to the second
quarter of 2019.
To cover its working capital requirement, the Company is
proposing that its shareholders should authorize one or more
capital increases reserved for Winance through the issue, in a
total amount of €5 million, of ordinary shares to which share
subscription warrants are attached and also authorize a capital
increase reserved for Vesalius Biocapital through the issue, in a
total amount of €250,000, of ordinary shares to which share
subscription Warrants are attached.
Indicative timetable for the Financing
February 15, 2019
EGM (quorum of 25% required at the first
time of calling) to approve theresolution permitting the reserved
issue of ABSAs to the Investor andVesalius Biocapital
March 4, 2019
EGM, if necessary, (quorum of 20% required
at the second time of calling) toapprove the resolution permitting
the reserved issue of ABSAs to the Investorand Vesalius
Biocapital
Late March 2019 at thelatest
Following the award by the Autorité des
Marchés Financiers of a visa to aprospectus to be filed by the
Company and of an exemption to Winance fromhaving to file a
mandatory public offer, Genomic Vision’s Management Boardshall meet
to consider the issue of ABSAs subject to EGM approvalSubscription
by the Investor of ABSA Tranche 1 in an amount of €1,500,000
Subscription by Vesalius Biocapital of
€250,000 of ABSA
Legal framework for the transaction
In accordance with the provisions of article L. 225-138 of the
French commercial code and subject to shareholder approval at the
extraordinary shareholders’ meeting to be convened on February 15,
2019, the Company’s Management Board would decide, in four tranches
to be allocated as stated below, and at the times it deems
appropriate, to proceed with one or more capital increases through
the issue of the Company’s ordinary shares to which share
subscription warrants (“Warrants”) are attached (together referred
to as “ABSAs” or shares with share subscription warrants attached),
which may be paid-up in cash, including through the offset of loans
in a nominal amount not exceeding €5 million, with
shareholders’ preferential subscription rights being waived in
favor of Winance (the “Investor”). The Company’s Management Board
would also decide to proceed with a capital increase through the
issue of the Company’s ordinary shares to which share subscription
warrants (“Warrants”) are attached (together referred to as “ABSAs”
or shares with share subscription warrants attached), which may be
paid-up in cash, including through the offset of loans in a nominal
amount not exceeding €250 thousand, with shareholders’
preferential subscription rights being waived in favor of Vesalius
Biocapital.
Key features of the ABSAs (shares to which share subscription
warrants are attached)
The shares to which share subscription warrants are attached
shall be the Company’s ordinary shares. They shall have the same
rights as those attached to the Company’s existing ordinary shares
and shall be admitted to the regulated Euronext market in Paris on
the same trading line (ISIN code: FR0011799907).
The maximum nominal amount of the capital increases that may be
carried out through the issue of ordinary shares to which share
subscription warrants are attached may not exceed €5,000,0000 for
the issue to Winance (the Investor) and €250,000 for the issue to
Vesalius Biocapital.
The issue price of the ordinary shares to be issued shall be 80%
of the lowest of the fifteen (15) final volume-weighted average
prices of the Company’s shares (as published by Bloomberg or any
other equivalent data provider where Bloomberg no longer publishes
the relevant data) preceding the day of the relevant issue. The
issue price may not be any lower than the nominal value of the
Company’s shares.
The issue of the shares to the Investor shall take place in four
tranches:
- Tranche 1 in an amount of
€1.5 million, including share premiums (additional paid-in
capital)
- Tranche 2 in an amount of
€1 million, including share premiums
- Tranche 3 in an amount of
€1 million, including share premiums
- Tranche 4 in an amount of
€1.5 million, including share premiums
The timetable for the issue of the tranches shall be determined
by the Company subject to the following time constraints:
- A period of 45 business days must ensue
between the drawdown of tranche 1 and tranche 2
- A period of 30 must ensue between
following drawdowns
The Investor may ask the Company to perform the minimum drawdown
on the first two tranches. The Investor may terminate the issue
agreement prior to its term should a material adverse change or a
change in control of the Company occur.
The issue of shares to Vesalius Biocapital shall take place on a
single occasion in an amount of €250,000, including the share
premium.
Key features of the share subscription warrants (“Warrants”)
attached to the new shares issued
The number of Warrants attached to each tranche of new shares
shall be calculated such that if all the Warrants are exercised,
the capital increase resulting from the exercise of said Warrants
(including the share premium) equals 30% of the nominal amount of
the corresponding tranche of new shares.
The Warrants shall immediately be detached from the ABSAs. The
Warrants may not be transferred by their holder without the prior
consent of the Company, with the exception of transfers undertaken
for the benefit of one or more of the Investor’s affiliates.
Furthermore, no application shall be made for the Warrants to be
admitted to trading on the regulated Euronext market in Paris.
Accordingly, they shall not be listed.
The Warrants may be exercised for a period of 5 years from their
issue (the “Exercise Period”).
Each Warrant shall entitle its holder to subscribe for one new
ordinary share in the Company during the Exercise Period.
The exercise price of the Warrants shall be 115% of the lowest
of the fifteen (15) final volume-weighted average prices of the
Company’s shares (as published by Bloomberg or any other equivalent
data provider where Bloomberg no longer publishes the relevant
data) immediately preceding the date of issue of the ABSAs from
which the Warrants are detached. The exercise price of the Warrants
may not be any lower than the nominal value of the Company’s
ordinary shares issued upon exercise of the Warrants.
Theoretical impact of the ABSA issue based on the lowest
daily volume-weighted average price of Genomic Vision shares
preceding January 8, 2019, i.e. €0.33
For guidance purposes, the impact of the issue of the first
drawdown and of all the ABSAs would be as follows:
- Impact of the issue on equity per share
(based on equity as stated in the interim financial statements for
the six-month period to June 30, 2018, prepared in accordance with
International Financial Reporting Standards (IFRS) and the number
of shares making up the Company’s share capital at January 8, 2019,
i.e., 16,656,208 shares):
Equity per share at June 30, 2018 (in €) Undiluted basis
Diluted basis1
Tranche 1 Total tranches Tranche 1
Total tranches Before issue 0.19 0.15
After the issue of 1,039,378 new shares
resulting fromconversion of the new shares and exercise of the
Warrantsgranted to Vesalius Biocapital
0.20 0.16
After the issue of 5,050,505 (Tranche 1)
or 16,835,016 (alltranches) new shares resulting from the
conversion of solelythe new shares granted to Winance, the
Investor
0.22 0.24 0.18 0.21
After the issue of 1,185,770 (Tranche 1)
or 3,952,569 (alltranches) new shares resulting from the exercise
of solely theWarrants granted to Winance, the Investor
0.21 0.23 0.16 0.19
After the issue of 6,236,275 (Tranche 1)
or 20,787,585 (alltranches) new shares resulting from the
conversion of thenew shares and exercise of the Warrants granted to
Winance,the Investor
0.22 0.26 0.19 0.23
After the issue of 1,039,378 new shares
resulting fromconversion of the new shares and exercise of the
Warrantsgranted to Vesalius Biocapital and 6,236,275 (Tranche 1)
or20,787,585 (all tranches) new shares resulting fromconversion of
the new shares and exercise of the Warrantsgranted to Winance, the
Investor
0.23 0.26 0.19 0.23
- Impact of the issue on the interest of
a shareholder currently owning 1% of the Company’s share
capital:
_______________1 assuming the exercise in full of the 10,000
share subscription warrants awarded to officers and directors, the
4,044,460 share subscription warrants granted to Bracknor and the
623,049 founder share warrants issued and awarded by the Company,
whether exercisable or not, giving rights respectively to the
subscription of 10,000, 4,044,460 and 623,049 shares. Given the
exercise price of these subscription warrants, no warrants may be
exercised at the January 8, 2019 price of €0.38, and so the impact
is theoretical only for guidance purposes.
Shareholder’s holding (as a %) Undiluted basis
Diluted basis2
Sensitivity to a reduction of 10%in the
VWAP, i.e., €0.297
Tranche 1 Total tranches Tranche 1
Total tranches Tranche 1 Total tranches Before
issue 1% 0.78% 0.78%
After the issue of 1,039,378 new shares
resultingfrom the conversion of new shares and exerciseof the
Warrants granted to Vesalius Biocapital
0.94% 0.74% 0.74%
After the issue of 5,050,505 (Tranche 1)
or16,835,016 (all tranches) new shares resultingfrom the conversion
of solely the new sharesgranted to Winance, the Investor
0.77% 0.50% 0.63% 0.44% 0.62%
0.42%
After the issue of 1,185,770 (Tranche 1)
or3,952,569 (all tranches) new shares resultingfrom the exercise of
solely the Warrants grantedto Winance
0.93% 0.81% 0.74% 0.66% 0.74%
0.65%
After the issue of 6,236,275 (Tranche 1)
or20,787,585 (all tranches) new shares resultingfrom the conversion
of the new shares andexercise of the Warrants granted to
Winance,the Investor
0.73% 0.44% 0.60% 0.40% 0.59%
0.37%
After the issue of 1,039,378 new shares
resultingfrom conversion of the new shares and exerciseof the
Warrants granted to Vesalius Biocapitaland 6,236,275 (Tranche 1) or
20,787,585 (alltranches) new shares resulting from theconversion of
the new shares and exercise of theWarrants granted to Winance, the
Investor
0.70% 0.43% 0.58% 0.39% 0.57%
0.37%
The dilution shall depend on the share price during the 15
business days immediately prior to the date of completion of the
issues of each ABSA tranche. A reduction of 10% in the lowest share
price would have additional dilutive impact as shown in the above
table.
Investor's Commitments
Winance will increase its holding to above the 30% threshold on
completion of the 1st tranche of €1.5 million, the 2nd tranche of
€1 million, or the 3rd tranche of €1 million depending on the share
price at the time of completion of the issue of each tranche, which
will trigger a mandatory public offering for all shares in
accordance with market regulations. Winance will therefore request
from the Autorité des Marchés Financiers an exemption from the
requirement to make a mandatory public offering under Article 234-9
paragraph 2 of the general regulations, on the basis that in the
absence of additional financing, the financial situation of Genomic
Vision presents financial difficulties and uncertainty on financial
visibility beyond the 2nd quarter of 2019.
Winance will also undertake to limit its share of voting rights
contractually to 20%, irrespective of its share of capital, in
order to confirm its intention not to find itself in a position
where it controls Genomic Vision.
_______________2 assuming the exercise in full of the 10,000
share subscription warrants awarded to officers and directors, the
4,044,460 share subscription warrants granted to Bracknor and the
623,049 founder share warrants issued and awarded by the Company,
whether exercisable or not, giving rights respectively to the
subscription of 10,000, 4,044,460 and 623,049 shares. Given the
exercise price for these subscription warrants, no warrants may be
exercised at the January 8, 2019 price of €0.38, and so the impact
is theoretical for guidance purposes.
Risk Factors
The main risk factors relating to new shares are set out
below:
- On the issuance of each tranche of new
shares, existing shareholders will see their holding in the
Company’s capital diluted; their holdings may also be diluted in
the event of the issuance of new shares on exercise of the
warrants.
- The total value of subscriptions for
the 4 tranches by Winance is not guaranteed.
- The volatility and liquidity of the
Company’s shares may fluctuate significantly.
- The sale of shares in the Company by
the Investor Winance on Euronext Paris could have a negative impact
on the market share price.
In addition, the Company invites its shareholders to refer to
the risk factors specific to the Company’s business activity as
described in the 2017 Annual Financial Report issued by the Company
on 28 April 2018.
Impact of the issue of new shares following the drawdown of
Tranche 1 of €1.5 million to the Investor Winance and the issue of
new shares for €250,000 to Vesalius Biocapital on the distribution
of capital and voting rights on the basis of an indicative share
price of €0.33
Before issue of shares with warrants After issue
of shares with warrants Shareholders Non-diluted
basis Diluted basis(1) Non-diluted basis
Diluted basis(1)
Number ofshares
% ofcapitalandvotingrights(2)
Number ofshares
% ofcapitalandvotingrights(2)
Number ofshares
% ofcapitalandvotingrights(2)
Number ofshares
% ofcapitalandvotingrights(2)
Aaron Bensimon 284,047 1.71% 673,596
3.16% 284,047 1.19% 673,596 2.35% Other
Directors 103,000 0.48%
103,000 0.36%
Other individuals(founders andmembers of
theScientificCommittee)
81,860 0.49% 81,860 0.38% 81,860
0.34% 81,860 0.29% Employees --
0.00% 140,500 0.66% -- 0.00%
140,500 0.49% Institut Pasteur 158,659 0.95%
158,659 0.74% 158,659 0.66%
158,659 0.55%
Quest DiagnosticsVentures
616,157 3.70% 616,157 2.89%
616,157 2.57% 616,157 2.15% Shares in Treasury
15,186 0.09% 15,186 0.07% 15,186
0.06% 15,186 0.05%
VesaliusBiocapital (3)
1,607,399 9.65% 1,607,399 7.53%
2,646,777 11.06% 2,646,777 9.25% Free float
13,892,900 83.41% 17,937,360 84.08%
13,892,900 58.05% 17,937,360 62.70%
Winance (Shareswith
warrantsincludingassociatedwarrants)
6,236,275 26.06% 6,236,275 21.80%
TOTAL
16,656,208 100.00% 21,333,717 100.00%
23,931,861 100.00% 28,609,370 100.00%
(1)
On the basis of fully diluted capital,
that is to say assuming that all warrants and “bons de souscription
de parts de créateursd’entreprise” (Business Creator Share
Warrants) in issue are exercised.
(2)
At the present date there are no shares
with double voting rights, and only shares held in treasury under
the liquidity contract arestripped of their voting rights. The
difference between percentage share ownership and percentage voting
rights is considered non-significant, due to the small number of
shares held in treasury, and is therefore not detailed in this
table.
(3)
To the best of the Company’s knowledge,
the shares held by Vesalius Biocapital through the Vesalius
Biocapital Holdings S.A. andVesalius Biocapital II Holding S.à.r.l.
funds are bearer shares, and the Company is not therefore in a
position to follow their distributionother than through
declarations relating to mandatory ownership thresholds.
Impact on the issue of all new shares
on the distribution of share capital and voting
rights
Before issue of shares with warrants After issue
of shares with warrants Shareholders Non-diluted
basis Diluted basis(1) Non-diluted basis
Diluted basis(1)
Number ofshares
% ofcapitalandvotingrights(2)
Number ofshares
% ofcapitalandvotingrights(2)
Number ofshares
% ofcapitalandvotingrights(2)
Number ofshares
% ofcapitalandvotingrights(2)
Aaron Bensimon 284,047 1.71% 673,596
3.16% 284,047 0.74% 673,596 1.56% Other
Directors - 0.00% 103,000 0.48%
- 0.00% 103,000 0.24%
Other individuals(founders andmembers of
theScientificCommittee)
81,860 0.49% 81,860 0.38% 81,860
0.21% 81,860 0.19% Employees -
0.00% 140,500 0.66% - 0.00%
140,500 0.33% Institut Pasteur 158,659 0.95%
158,659 0.74% 158,659 0.41%
158,659 0.37%
Quest DiagnosticsVentures
616,157 3.70% 616,157 2.89%
616,157 1.60% 616,157 1.43% Shares in Treasury
15,186 0.09% 15,186 0.07% 15,186
0.04% 15,186 0.04%
VesaliusBiocapital (3)
1,607,399 9.65% 1,607,399 7.53%
2,646,777 6.88% 2,646,777 6.13% Free float
13,892,900 83.41% 17,937,360 84.08%
13,892,900 36.10% 17,937,360 41.56%
Winance (Shareswith
warrantsincludingassociatedwarrants)
0.00% - 0.00% 20,787,585
54.02% 20,787,585 48.16%
TOTAL
16,656,208 100.00% 21,333,717 100.00%
38,483,171 100.00% 43,160,680 100.00% (1)
On the basis of fully diluted capital,
that is to say assuming that all warrants and “bons de souscription
de parts de créateursd’entreprise” (Business Creator Share
Warrants) in issue are exercised.
(2)
At the present date there are no shares
with double voting rights, and only shares held in treasury under
the liquidity contract arestripped of their voting rights. The
difference between percentage share ownership and percentage voting
rights is considered non-significant, due to the small number of
shares held in treasury, and is therefore not detailed in this
table.
(3)
To the best of the Company’s knowledge,
the shares held by Vesalius Biocapital through the Vesalius
Biocapital Holdings S.A. andVesalius Biocapital II Holding S.à.r.l.
funds are bearer shares, and the Company is not therefore in a
position to follow their distributionother than through
declarations relating to mandatory ownership thresholds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190110005712/en/
Genomic VisionAaron BensimonCo-founder, Chairman &
CEOTel.: +33 1 49 08 07 50investisseurs@genomicvision.comUlysse
CommunicationPress RelationsBruno ArabianTel.: +33 1 42
68 29 70barabian@ulysse-communication.comNewCapInvestor
Relations& Strategic CommunicationsTel.: +33 1 44 71
94 94gv@newcap.eu
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024